This is following a strategic review of the Teva-Lonza Joint Venture.
The discontinuation of the TL-JV, which began in 2009, will enable both companies to better advance their own strategies and efforts in serving those healthcare communities.
Both companies will continue to explore opportunities to maximise the value of the investments and progress that the joint venture has made to this point, and remain in agreement that affordable, efficacious and safe biosimilar treatments will bring benefits to patients and better serve these communities.
© FoodBev Media Ltd 2024